Drug class
Mitochondria-targeted tetrapeptide; cardiolipin-binding mitochondrial modulator
Mechanism of action
Binds cardiolipin in the inner mitochondrial membrane and localises to the inner mitochondrial membrane, where it is intended to improve mitochondrial structure and function. The clinical mechanism underlying increased muscle strength in Barth syndrome is not fully established.
General use cases
- To improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg under the US FDA FORZINITY accelerated-approval indication (September 19 2025)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
